Correlations of β-catenin, Ki67 and Her-2/neu with gastric cancer

Asian Pacific Journal of Tropical Medicine

Volumn 7, Issue 4, 2014, Pages 257-261

  Wu, Hong Wen ^a   Qin, Cheng Yong ^b   Huang, Ji Lai ^c   Kong, Xian Yi ^c   Wang, Wen Ji ^d   Bai, Wen Kun ^d  

^a SHANDONG UNIVERSITY   (China)

^b First Hospital of Zibo   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

catenin; Fluorescence in situ hybridization; Gastric cancer; Her 2 neu; Immunohistochemistry; Ki67; Tumor marker

Indexed keywords

FLUORESCENCE IN SITU HYBRIDIZATION; GASTRIC CANCER; HER-2/NEU; IMMUNOHISTOCHEMISTRY; KI67; TUMOR MARKER; Β-CATENIN;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STATISTICS, NONPARAMETRIC; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893461804     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1995-7645(14)60033-X     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Hu SL, Kong XY, Cheng ZD, Sun YB, Shen G, Xu WP, et al. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma. Tumori 2010, 96:726-733.
3. Xu L, Jiang Y, Zheng J, Xie G, Li J, Shi L, et al. Aberrant expression of β-catenin and E-cadherin is correlated with poor prognosis of nasopharyngeal cancer. Hum Pathol 2013, 44:1357-1364.
4. Luo W, Fang W, Li S, Yao K Aberrant expression of nuclear vimentin and related epithelial-mesenchymal transition markers in nasopharyngeal carcinoma. Int J Cancer 2012, 131:1863-1873.
5. Ma L, Zhang G, Miao XB, Deng XB, Wu Y, Liu Y, Jin ZR, et al. Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. FEBS J 2013, 280:2027-2041.
6. Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 2012, 11:73.
7. Ma BB, Lui VW, Poon FF, Wong SC, To KF, Wong E, et al. Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs 2010, 28:326-333.
8. Gaujoux S, Hantel C, Launay P, Bonnet S, Perlemoine K, Lefèvre L, et al. Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R. PLoS One 2013, 8:e55743.
9. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré AM, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005, 65:7622-7627.
10. Chapman A, Durand J, Ouadi L, Bourdeau I Identification of genetic alterations of AXIN2 gene in adrenocortical tumors. J Clin Endocrinol Metab 2011, 96:E1477-E1481.
11. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008, 372:392-397.
12. Tadjine M, Lampron A, Ouadi L, Bourdeau I Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) 2008, 68:264-270.
13. Wang JX, Zhang YY, Yu XM, Jin T, Pan XL Role of centromere protein H and Ki67 in relapse-free survival of patients after primary surgery for hypopharyngeal cancer. Asian Pac J Cancer Prev 2012, 13:821-825.
14. He WL, Li YH, Yang DJ, Song W, Chen XL, Liu FK, et al. Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patients with gastric carcinoma. Eur J Surg Oncol 2013, 39:141-149.
15. Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, et al. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 2012, 135:619-627.
16. He WL, Li YH, Yang DJ, Song W, Chen XL, Liu FK, et al. Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patients with gastric carcinoma. Eur J Surg Oncol 2013, 39:141-149.
17. Meza-Junco J, Sawyer MB Metastatic gastric cancer - focus on targeted therapies. Biologics 2012, 6:137-146.
18. Meza-Junco J, Au HJ, Sawyer MB Trastuzumab for gastric cancer. Expert Opin Biol Ther 2009, 9:1543-1551.